| AGM Update | Nov 19, 2026 | Meeting notice | ASX |
|---|
| Notices under sections 203D and 249D of the Corporations Act | Nov 19, 2026 | Other filings | ASX |
|---|
| Application for quotation of securities - AN1 | Nov 15, 2026 | Financing | ASX |
|---|
| Proposed issue of securities - AN1 | Nov 11, 2026 | Financing | ASX |
|---|
| Anagenics to Acquire Bio-First Skincare Brand | Nov 10, 2026 | Acquisition or disposal | ASX |
|---|
| Sale of Intellectual Property and Earn-Out Arrangement | Nov 4, 2026 | Acquisition or disposal | ASX |
|---|
| Pause in Trading | Nov 4, 2026 | Trading halt or suspension | ASX |
|---|
| AN1 - Appendix 4C & Activity Report for Q1 FY2027 | Oct 22, 2026 | Quarterly report | ASX |
|---|
| Notice of Annual General Meeting/Proxy Form | Oct 5, 2026 | Meeting notice | ASX |
|---|
| AN1 FY26-Appendix-4E- | Aug 28, 2026 | Results | ASX |
|---|
| AN1 - Appendix 4G JUN 2026 | Aug 28, 2026 | Other filings | ASX |
|---|
| AN1 2026 Annual Report | Aug 28, 2026 | Annual report | ASX |
|---|
| Appendix 4C & Activity Report for Q4 FY2026 | Jul 29, 2026 | Quarterly report | ASX |
|---|
| Change of Auditor | Jul 27, 2026 | Management or board change | ASX |
|---|
| AN1 - Appendix 4C & Activity Report for Q3 FY2026 | Apr 27, 2026 | Quarterly report | ASX |
|---|
| Anagenics - 1H FY26 Result Highlights | Feb 24, 2026 | Results | ASX |
|---|
| Appendix 4D 1H FY26 DEC 2025 | Feb 24, 2026 | Interim report | ASX |
|---|
| Appendix 4C & Activity Report for Q2 FY2026 | Jan 29, 2026 | Quarterly report | ASX |
|---|
| Placement of Shares | Dec 9, 2025 | Financing | ASX |
|---|
| Trading Halt | Dec 7, 2025 | Trading halt or suspension | ASX |
|---|
| Appendix 4C & Activity Report for Q1 FY2026 | Oct 30, 2025 | Quarterly report | ASX |
|---|
| AN1 - FY 2025 Presentation | Aug 28, 2025 | Results | ASX |
|---|
| AN1 FY25-Appendix-4E-Preliminary-Final-Report | Aug 27, 2025 | Results | ASX |
|---|
| Activity Report & Appendix 4C Q4 FY2025 | Jul 28, 2025 | Quarterly report | ASX |
|---|
| YSB Bouf Haircare Continues Strong Performance | Jun 27, 2025 | Operations update | ASX |
|---|
| York Street Brands Product Launch | Jun 4, 2025 | Operations update | ASX |
|---|
| AN1 - 3Q25 Presentation | May 4, 2025 | Quarterly report | ASX |
|---|
| Reinstatement to Quotation | May 2, 2025 | Trading halt or suspension | ASX |
|---|
| AN1 - Pre-reinstatement Disclosure | May 2, 2025 | Other filings | ASX |
|---|
| AN1 3Q25 Activity Report | May 1, 2025 | Quarterly report | ASX |
|---|
| Appendix 4C Cash Flow Report | May 1, 2025 | Quarterly report | ASX |
|---|
| Long Term Suspended Entities | Apr 9, 2025 | Trading halt or suspension | ASX |
|---|
| AN1 - 1H25 Update | Feb 27, 2025 | Interim report | ASX |
|---|
| AN1 - Appendix 4D 1H FY2025 | Feb 27, 2025 | Interim report | ASX |
|---|
| Update on 2Q25 Activity Report | Feb 10, 2025 | Quarterly report | ASX |
|---|
| Q2 F25 Activity Statement and Appendix 4C | Jan 31, 2025 | Quarterly report | ASX |
|---|
| Restructuring Update & Resignation of Director | Oct 31, 2024 | Operations update | ASX |
|---|
| Q1 F25 Activity Statement and Appendix 4C | Oct 31, 2024 | Quarterly report | ASX |
|---|
| Market Update | Oct 2, 2024 | Acquisition or disposal | ASX |
|---|
| Suspension from Official Quotation | Sep 3, 2024 | Trading halt or suspension | ASX |
|---|
| Pause in Trading | Sep 2, 2024 | Trading halt or suspension | ASX |
|---|
| FY24 4E Presentation | Aug 30, 2024 | Results | ASX |
|---|
| Appendix 4E and Preliminary Final Report | Aug 30, 2024 | Results | ASX |
|---|
| Company Update License Partnership Announcement | Jul 23, 2024 | Operations update | ASX |
|---|
| Appendix 4C Cash Flow & Activities Report | Jul 23, 2024 | Quarterly report | ASX |
|---|
| Midkine Antibody Licensing Deal | May 24, 2024 | Other filings | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Apr 28, 2024 | Quarterly report | ASX |
|---|
| Organisational Changes | Mar 7, 2024 | Management or board change | ASX |
|---|
| H1 FY24 Results and Corporate Update | Feb 26, 2024 | Results | ASX |
|---|
| Appendix 4D and Half Year Report | Feb 26, 2024 | Interim report | ASX |
|---|
| Investor Presentation | Feb 6, 2024 | Other filings | ASX |
|---|
| Completion of Placement | Feb 6, 2024 | Financing | ASX |
|---|
| Appendix 4C and Quarterly Activity Report | Oct 30, 2023 | Quarterly report | ASX |
|---|
| Business Update | Oct 1, 2023 | Acquisition or disposal | ASX |
|---|
| Acquisition of Face MediGroup Presentation | Aug 22, 2023 | Acquisition or disposal | ASX |
|---|
| Anagenics to Acquire Face MediGroup | Aug 22, 2023 | Acquisition or disposal | ASX |
|---|
| FY23 Financial Performance and Business Update | Jun 27, 2023 | Operations update | ASX |
|---|
| CEO Appointment | Mar 28, 2023 | Other filings | ASX |
|---|
| Results of Institutional Entitlement Offer | Feb 15, 2023 | Financing | ASX |
|---|
| Entitlement Offer and Company Update | Feb 13, 2023 | Financing | ASX |
|---|
| Corporate Update and Acquisition | Dec 8, 2022 | Acquisition or disposal | ASX |
|---|
| Appendix 4E and FY22 Financial Report | Aug 24, 2022 | Results | ASX |
|---|
| Advangen Japan Divestment and Earn-Out Agreement | Jul 25, 2022 | Acquisition or disposal | ASX |
|---|
| Appointment of Exec Director, Corporate and Trading Update | Jul 7, 2022 | Management or board change | ASX |
|---|
| New Leadership Driving Business Transformation | Mar 15, 2022 | Other filings | ASX |
|---|
| Anagenics Appoints CEO | Feb 28, 2022 | Other filings | ASX |
|---|
| Anagenics Board and Leadership Transition | Feb 15, 2022 | Other filings | ASX |
|---|
| Second Supply Agreement for Anagenics FGF5 Inhibitors | Dec 23, 2021 | Other filings | ASX |
|---|
| BLC Cosmetics Acquisition Completed | Nov 1, 2021 | Acquisition or disposal | ASX |
|---|
| Investor Webinar | Sep 26, 2021 | Other filings | ASX |
|---|
| HNG: BLC Cosmetics to merge with Cellmid | Sep 15, 2021 | Other filings | ASX |
|---|
| Cellmid to Acquire BLC Cosmetics Pty Ltd | Sep 15, 2021 | Acquisition or disposal | ASX |
|---|
| Appendix 4E and FY21 Financial Report | Aug 19, 2021 | Results | ASX |
|---|
| Cellmid Reports Record QVC Sales | Jun 16, 2021 | Other filings | ASX |
|---|
| Supply Agreement for Cellmids FGF5 Inhibitors | Jun 8, 2021 | Other filings | ASX |
|---|
| Chinese Import Permits Received | Apr 30, 2021 | Other filings | ASX |
|---|
| Agreement Signed for Sale of Lyramid Limited | Apr 29, 2021 | Other filings | ASX |
|---|
| Supplementary Prospectus | Mar 31, 2021 | Offer document | ASX |
|---|
| Rights Issue Closed with Strong Demand | Mar 31, 2021 | Financing | ASX |
|---|
| Rights Issue Prospectus | Mar 8, 2021 | Financing | ASX |
|---|
| Rights Issue | Mar 7, 2021 | Financing | ASX |
|---|
| Cellmid Publishes Data on Novel Proprietary FGF5 Aptamer | Feb 8, 2021 | Other filings | ASX |
|---|
| Cellmid Receives First Order From Chinese Distributor | Jan 24, 2021 | Other filings | ASX |
|---|
| Cellmid Signs 10 Year Chinese Distribution Agreement | Dec 13, 2020 | Other filings | ASX |
|---|
| Growth Strategy Presentation | Nov 11, 2020 | Other filings | ASX |
|---|
| FY20 Financial Results | Aug 27, 2020 | Results | ASX |
|---|
| Appendix 4E and FY20 Financial Report | Aug 27, 2020 | Results | ASX |
|---|
| CDY Signs Agreement With Premium Salon Distributor in USA | Jul 28, 2020 | Other filings | ASX |
|---|
| Response to ASX Aware Query | Jul 9, 2020 | Explanation request | ASX |
|---|
| Cellmid Signs Exclusive Agreement For Sars-Cov-2 Laboratory | Jul 8, 2020 | Other filings | ASX |
|---|
| Extension Of Wondfo Rapid Test Distribution Agreement | Jul 2, 2020 | Other filings | ASX |
|---|
| Cellmid Reports on Strong QVC Sales Event | Jun 15, 2020 | Other filings | ASX |
|---|
| Cellmid Reports on Results of The Doherty Institute Testing | Jun 14, 2020 | Other filings | ASX |
|---|
| CDY signs Introducer Agreement to broaden product offering | Jun 4, 2020 | Other filings | ASX |
|---|
| Appointment of Dr Dominic Burg as Chief Operating Officer | Jun 1, 2020 | Management or board change | ASX |
|---|
| Cellmids Alopecia Patent Allowed in Australia and Japan | Apr 24, 2020 | Other filings | ASX |
|---|
| Independent Test Results For The Wondfo SARS-CoV-2 Test | Apr 22, 2020 | Other filings | ASX |
|---|
| Cellmids Shipment of SARS-CoV-2 Tests Received | Apr 14, 2020 | Other filings | ASX |
|---|
| Reinstatement to Official Quotation | Apr 7, 2020 | Trading halt or suspension | ASX |
|---|
| Response to ASX Query Letter | Apr 6, 2020 | Explanation request | ASX |
|---|
| Market Update on COVID-19 | Mar 27, 2020 | Other filings | ASX |
|---|
| Appendix 4D, Half Year Accounts and Presentation | Feb 26, 2020 | Interim report | ASX |
|---|
| Cellmids Evolis Patent to be Granted in China | Feb 3, 2020 | Other filings | ASX |
|---|
| Appendix 4C and Notes to Appendix 4C | Jan 29, 2020 | Quarterly report | ASX |
|---|
| Key Midkine Antibody Patents Granted in the US and Europe | Jan 5, 2020 | Other filings | ASX |
|---|
| Cellmid Reports on QVC Sales | Dec 5, 2019 | Other filings | ASX |
|---|
| Cellmid Signs Trading Agreement With API/Priceline | Nov 5, 2019 | Other filings | ASX |
|---|
| New TV Shopping Agreement for Evolis | Oct 13, 2019 | Other filings | ASX |
|---|
| New Evolis Distribution & Supply Agreements - China & Europe | Oct 1, 2019 | Other filings | ASX |
|---|
| FY2019 Financial Results | Aug 28, 2019 | Results | ASX |
|---|
| Patent for Improved Midkine Antibody Allowed in Europe | Aug 22, 2019 | Other filings | ASX |
|---|
| CDY Signs Distribution Agreement for EVOLIS in South Korea | Aug 5, 2019 | Other filings | ASX |
|---|
| Response to Appendix 4C Query | Aug 1, 2019 | Quarterly report | ASX |
|---|
| Cellmid Sets Another Sales Record in Q4 FY2019 | Jul 4, 2019 | Other filings | ASX |
|---|
| Cellmids Evolis Registered in European Union (EU) | Apr 30, 2019 | Other filings | ASX |
|---|
| Minimum Holding Share Buy-Back | Mar 18, 2019 | Treasury share status | ASX |
|---|
| Appendix 4D, Half Year Accounts and Strategy Update | Feb 21, 2019 | Interim report | ASX |
|---|
| Significant New Findings Published on Midkine | Feb 7, 2019 | Other filings | ASX |
|---|
| Cellmid Expects Record Sales in Q2 FY2019 | Dec 11, 2018 | Other filings | ASX |
|---|
| Cellmid Appoints Exclusive New Zealand Distributor | Nov 18, 2018 | Other filings | ASX |
|---|
| New Patents for Midkine Antibodies in USA and Europe | Nov 6, 2018 | Other filings | ASX |
|---|
| Ikon Legal Action - Decision | Nov 2, 2018 | Other filings | ASX |
|---|
| Cellmids Evolis Successfully Launched in USA stores | Oct 31, 2018 | Other filings | ASX |
|---|
| Change of Registry Address: Automic P/L - Sydney Office | Sep 28, 2018 | Other filings | ASX |
|---|
| Lead Antibody Effective in Rare Chronic Kidney Disease | Sep 12, 2018 | Other filings | ASX |
|---|
| Cellmid Share Purchase Plan Completion | Sep 2, 2018 | Financing | ASX |
|---|
| Evolis USA Distribution Update | Aug 30, 2018 | Other filings | ASX |
|---|
| Preliminary Final Report | Aug 24, 2018 | Results | ASX |
|---|
| Cleansing Notice and Appendix 3B | Aug 6, 2018 | Financing | ASX |
|---|
| Cellmid Share Purchase Plan | Jul 31, 2018 | Financing | ASX |
|---|
| Cellmid Share Placement Raises $9M | Jul 30, 2018 | Financing | ASX |
|---|
| CELLMID UPDATES ON DISTRIBUTION OF EVOLIS | Jul 10, 2018 | Other filings | ASX |
|---|
| CELLMID TO COMMENCE SELLING OF EVOLIS INTO CHINESE MARKET | May 2, 2018 | Other filings | ASX |
|---|
| CELLMID SECURES BLOOMINGDALES USA PARTNERSHIP FOR EVOLIS | Apr 23, 2018 | Other filings | ASX |
|---|
| Appendix 4C - quarterly | Apr 22, 2018 | Quarterly report | ASX |
|---|
| CELLMID SIGNS DISTRIBUTION AGREEMENT FOR FILLERINA | Apr 4, 2018 | Other filings | ASX |
|---|
| Appendix 4D and Half Year Accounts | Feb 21, 2018 | Interim report | ASX |
|---|
| RECORD 2M SALES FOR CELLMID FGF5 INHIBITORS | Jan 9, 2018 | Other filings | ASX |
|---|
| CELLMID QUARTERLY OPERATIONAL UPDATE | Jan 8, 2018 | Other filings | ASX |
|---|
| CELLMID PLACEMENT TO STRATEGIC INVESTOR | Dec 15, 2017 | Financing | ASX |
|---|
| CELLMID SECURES NEW US RETAIL PARTNER FOR EVOLIS | Dec 6, 2017 | Other filings | ASX |
|---|
| CELLMID OPENS FIRST CONCEPT STORE IN TOKYO | Oct 25, 2017 | Other filings | ASX |
|---|
| PROPOSED CONSOLIDATION OF SECURITIES | Oct 23, 2017 | Other filings | ASX |
|---|
| CELLMID RECEIVES $947K R&D TAX CREDIT | Oct 2, 2017 | Other filings | ASX |
|---|
| CELLMID COMPLETES US CONSUMER STUDY | Aug 20, 2017 | Other filings | ASX |
|---|
| CELLMID SECURES PREMIUM US RETAIL CHANNEL FOR EVOLIS | Aug 2, 2017 | Other filings | ASX |
|---|
| Nature Paper MK in Melanoma | Jul 3, 2017 | Other filings | ASX |
|---|
| CELLMIDS FGF5 INHIBITOR CLINICAL STUDY PUBLISHED | Mar 2, 2017 | Other filings | ASX |
|---|
| Cellmid to Refinance R&D Loan Facility | Mar 1, 2017 | Other filings | ASX |
|---|
| MIDKINE ALOPECIA PATENT EUROPEAN ALLOWANCE | Feb 6, 2017 | Other filings | ASX |
|---|
| CELLMIDS USA MIDKINE PATENT FOR ALOPECIA ALLOWED | Jan 30, 2017 | Other filings | ASX |
|---|
| Appendix 4C | Jan 23, 2017 | Quarterly report | ASX |
|---|
| CELLMID RECEIVES AUSTRALIAN GOVT GRANT FOR MIDKINE PROGRAMME | Jan 18, 2017 | Other filings | ASX |
|---|
| Cellmid Updates on CxBladder License | Dec 12, 2016 | Other filings | ASX |
|---|
| Cellmid receives 831K R&D tax credit | Nov 29, 2016 | Other filings | ASX |
|---|
| USA launch of evolis | Nov 2, 2016 | Other filings | ASX |
|---|
| ASX Market Release - Reinstatement | Oct 31, 2016 | Other filings | ASX |
|---|
| CELLMID RECORDS HIGHEST EVER QUARTERLY SALES FOR EVOLIS | Oct 10, 2016 | Other filings | ASX |
|---|
| Midkine Antibodies Show Anti-Tumor Activity In Brain Cancer | Oct 5, 2016 | Other filings | ASX |
|---|
| European Midkine Patent For Surgical Adhesion Allowed | Sep 22, 2016 | Other filings | ASX |
|---|
| New Publication for Cellmids Midkine Antibody | Aug 9, 2016 | Other filings | ASX |
|---|
| Transcript of Cellmid Investor Briefing Call | Jul 29, 2016 | Other filings | ASX |
|---|
| CDY: Ikon Legal Action | Jul 22, 2016 | Other filings | ASX |
|---|
| USA Distribution Partnership for Cellmids Evolis | Jul 19, 2016 | Other filings | ASX |
|---|
| MK antibody publication and patent in bone healing | Jun 24, 2016 | Other filings | ASX |
|---|
| Midkine Strategy Update | Apr 8, 2016 | Other filings | ASX |
|---|
| Response to ASX Query | Mar 30, 2016 | Explanation request | ASX |
|---|
| Cellmid to Refinance RnD Loan | Feb 26, 2016 | Other filings | ASX |
|---|
| Cellmid receives $1.12M R&D Tax Credit | Feb 11, 2016 | Other filings | ASX |
|---|
| Key Antibody Patent Granted in Europe | Feb 10, 2016 | Other filings | ASX |
|---|